Other Posts
Larvol announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the MAPS Annual Conference in New Orleans, LA. The Omni platform, available on both desktop and mobile devices, offers users the ability to track developments related to Key Opinion Leaders, including conferences, social media, and clinical trials in real time.
SAN FRANCISCO–(BUSINESS WIRE) – Larvol, a San Francisco-based pharma SaaS (Software as a Service) company, announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the Medical Affairs Professional Society Annual Conference in New Orleans, LA. The Omni platform, available on both desktop and mobile devices, offers users the ability to track developments related to Key Opinion Leaders, including conferences, social media, and clinical trials in real time.
“We were emboldened by the feedback we received from our customers to develop a dynamic platform that can be widely adopted by Med Comm and Med Affairs teams as well as CI pros who have been relying on our solutions in the pharma industry for more than a decade,” said CEO Dr. Aviva Fridman. “I am excited to get Omni into the hands of customers who will benefit from instant access to their market and KOL data.”
Omni enables users to choose their target KOLs and access their activity instantly via their desktop or mobile device. Features include:
Larvol provides SaaS solutions that support competitive intelligence, business intelligence, and medical communications departments in the pharmaceutical and biotech industry. Their products include secondary competitive intelligence reports, KOL tracking, and conference planning solutions. Larvol curates pharmaceutical and biotech competitive intelligence using a proven combination of broad therapeutic-area expertise and technological innovation to keep their customers at the forefront of the industry. The Larvol team consists of MDs and PhDs who curate data from over 25,000 sources and distill the most relevant findings into concise reports that provide real-time insights and time-saving analysis.
For more information about Larvol or sales inquiries, please contact us at info@larvol.com. New users can register at www.larvolomni.com.
Contacts
Larvol
info@larvol.com
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
